申请人:Dainippon Pharmaceutical Co., Ltd.
公开号:US05017573A1
公开(公告)日:1991-05-21
An indazole-3-carboxylic acid derivative represented by the following general formula (I) or its physiologically acceptable acid addition salt or quaternary ammonium salt, ##STR1## wherein Y represents --NH-- or --O--; R.sub.1 and R.sub.2 are identical or different and each represents a hydrogen atom, a lower alkyl group, a substituted lower alkyl group, a cycloalkyl group, a lower alkenyl group, a cycloalkenyl group, a lower alkynyl group, an unsubstituted or substituted aryl-lower alkyl group, a lower alkoxycarbonyl group, an unsubstituted or substituted aralkyloxycarbonyl group or an acyl group, or R.sub.1 and R.sub.2, taken together, form a lower alkylene group; R.sub.3 represents a hydrogen atom, a lower alkyl group, or a phenyl group; R.sub.4 represents a hydrogen atom, a lower alkyl group, a substituted lower alkyl group, a cycloalkyl group, a lower alkenyl group, a cycloalkenyl group, a lower alkynyl group, an unsubstituted or substituted aryl-lower alkyl group, a lower alkoxycarbonyl group, an unsubstituted or substituted aralkyloxycarbonyl group or an acyl group; R.sub.5 represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a hydroxyl group, a trifluoromethyl group, a nitro group, an amino group or an acylamino group; m represents a number of 1, 2, 3 or 4; n represents a number of 1, 2 or 3; and p represents a number of 1, 2, 3 or 4. This compound is useful as a potent and selective antagonist of serotonin 3 (5--HT.sub.3) receptor.
以下是一种以吲唑-3-羧酸为基础的衍生物,其化学式为(I),或其生理上可接受的酸加成盐或季铵盐: ##STR1## 其中,Y代表--NH--或--O--;R.sub.1和R.sub.2相同或不同,每个代表氢原子、较低的烷基、取代的较低烷基、环烷基、较低烯基、环烯基、较低炔基、未取代或取代的芳基-较低烷基、较低烷氧羰基、未取代或取代的芳基-烷氧羰基、或酰基,或R.sub.1和R.sub.2一起形成较低的烷基;R.sub.3代表氢原子、较低的烷基或苯基;R.sub.4代表氢原子、较低的烷基、取代的较低烷基、环烷基、较低烯基、环烯基、较低炔基、未取代或取代的芳基-较低烷基、较低烷氧羰基、未取代或取代的芳基-烷氧羰基、或酰基;R.sub.5代表氢原子、卤原子、较低的烷基、较低的烷氧基、羟基、三氟甲基、硝基、氨基或酰胺基;m代表1、2、3或4;n代表1、2或3;p代表1、2、3或4。该化合物可作为5-羟色胺3(5-HT.sub.3)受体的有效选择性拮抗剂。